JP5890769B2 - がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp) - Google Patents
がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp) Download PDFInfo
- Publication number
- JP5890769B2 JP5890769B2 JP2012272828A JP2012272828A JP5890769B2 JP 5890769 B2 JP5890769 B2 JP 5890769B2 JP 2012272828 A JP2012272828 A JP 2012272828A JP 2012272828 A JP2012272828 A JP 2012272828A JP 5890769 B2 JP5890769 B2 JP 5890769B2
- Authority
- JP
- Japan
- Prior art keywords
- fsp
- vaccine
- vector
- cancer
- msi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 20
- 238000011282 treatment Methods 0.000 title claims description 9
- 230000037433 frameshift Effects 0.000 title claims description 7
- 230000002265 prevention Effects 0.000 title claims description 5
- 201000011510 cancer Diseases 0.000 title description 21
- 102000004196 processed proteins & peptides Human genes 0.000 title description 5
- 229960005486 vaccine Drugs 0.000 claims description 27
- 108091007433 antigens Proteins 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 16
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 10
- 108060000255 AIM2 Proteins 0.000 claims description 8
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 claims description 8
- 101000837903 Homo sapiens TATA box-binding protein-associated factor RNA polymerase I subunit B Proteins 0.000 claims description 8
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 claims description 8
- 102100028546 TATA box-binding protein-associated factor RNA polymerase I subunit B Human genes 0.000 claims description 8
- 238000002255 vaccination Methods 0.000 claims description 7
- 241000710929 Alphavirus Species 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 241000700663 Avipoxvirus Species 0.000 claims description 2
- 241000178270 Canarypox virus Species 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241000700662 Fowlpox virus Species 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
- 208000032818 Microsatellite Instability Diseases 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 13
- 230000028993 immune response Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 9
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 8
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000005867 T cell response Effects 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 6
- 201000005027 Lynch syndrome Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 230000024932 T cell mediated immunity Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000033607 mismatch repair Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000007402 cytotoxic response Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000029709 cellular response to tumor cell Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000027296 dendritic cell chemotaxis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000021991 hereditary neoplastic syndrome Diseases 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
(a)フレームシフトペプチド(FSP)はMSI特異的であり、MSI腫瘍の病因に直接起因し、
(b)臨床的に関連する副作用がないことが期待され、
(c)FSPの組合せ(複数)がMSIを有する全ての腫瘍を標的とすることが予測され、
(d)FSPワクチン接種が、結腸がんの15%、並びに子宮内膜、胃、小腸及び他の臓器の腫瘍の治療のために設計されており、
(e)分子腫瘍分析により、FSPワクチン接種(標的療法)の恩恵を受けることができる患者を特定することができ、
(f)FSPワクチン接種を高リスク群における予防ワクチン接種として使用することができる。
(a)以下のアミノ酸配列を含むか又はそれからなるFSP:
NTQIKALNRGLKKKTILKKAGIGMCVKVSSIFFINKQKP(TAF1B(−1))、
EIFLPKGRSNSKKKGRRNRIPAVLRTEGEPLHTPSVGMRETTGLGC(HT001(−1))、
HSTIKVIKAKKKHREVKRTNSSQLV(AIM2(−1))、若しくは
ASPKCIMKEKKSLVRLSSCVPVALMSAMTTSSSQKNITPAILTCC(TGFBR2(−1))、
(b)(a)のFSPの機能的等価物、又は
(c)(a)及び/若しくは(b)のFSPの組合せ、
を含有する。
MSI結腸がんを有する患者及び健常なHNPCC突然変異保因者由来の末梢血中のFSP特異的なT細胞の検出
(A)方法(ELISpotアッセイ)
FSP特異的な末梢T細胞(pTc)の頻度を、ELISpot分析を用いて、3cMS含有候補遺伝子から誘導される新たに設計されたFSPに対して特異的なIFN−γ分泌型のTcの数を決定することにより定量した。ELISpotアッセイを、マウス抗ヒトIFN−γモノクローナル抗体(mAb)(Mabtech, Nacka, Sweden)で一晩コーティングし、血清含有培地を用いてブロッキングした96ウェルニトロセルロースプレート(Multiscreen;Millipore, Bedford, MA)を用いて実施した。pTc(0日、1×105/ウェル)を、10% ヒトAB血清を有する200μlのIMDM中で抗原提示細胞である自己CD40活性化B細胞(それぞれ、4×104/ウェル、TiBc又はpBc)とともに、6重で(6-fold)プレーティングした。ペプチドを最終濃度が10μg/mLとなるように添加した。陽性対照として、pTcを、350nmol/Lのイオノマイシンと組み合わせて20nmol/Lのホルボール−12−ミリステート−13−アセテートで処理した。37℃で24時間のインキュベーション後、プレートを十分に洗浄して、ビオチン化ウサギ抗ヒトIFN−γ mAbと4時間インキュベートして、再び洗浄し、ストレプトアビジン−アルカリホスファターゼと2時間インキュベートした後、最後の洗浄工程を行った。スポットを1時間のNBT/BCIP(Sigma-Aldrich)とのインキュベーションにより検出し、水を用いて反応を停止させ、乾燥後に顕微鏡によってスポットをカウントした。方法はSchwitalle et al., 2008において詳細に記載されている。
FSP特異的なT細胞応答がMSI−H CRC患者の末梢血中で検出可能であるかどうかを調べるために、ELISpot分析を実施した。MHCクラスI及びIIの高い発現を示す自己pBcと、共刺激因子(CD40、CD80及びCD86)と、B細胞特異的抗原(CD19及びCD23)とを抗原提示細胞として使用した。
TAF1B(−1) NTQIKALNRGLKKKTILKKAGIGMCVKVSSIFFINKQKP
HT001(−1) EIFLPKGRSNSKKKGRRNRIPAVLRTEGEPLHTPSVGMRETTGLGC
AIM2(−1) HSTIKVIKAKKKHREVKRTNSSQLV
TGFBR2(−1) ASPKCIMKEKKSLVRLSSCVPVALMSAMTTSSSQKNITPAILTCC
(ネオペプチド配列は下線処理している)
MSI結腸がんを有する患者及び健常なHNPCC突然変異保因者由来の末梢血中でのFSP特異的な体液性免疫応答の検出
(A)方法(ELISA)
酵素結合免疫吸着測定法(ELISA)のために、ペプチドをPBS中、4℃で40μg/mlの濃度で96ウェルポリスチロールマイクロタイタープレート「Maxisorp」(Nunc, Roskilde, Denmark)に一晩コーティングした。コーティング後、プレートをPBS(0.05% Tween)で4回洗浄し、PBS中の0.5% カゼインを用いて1時間ブロッキングした。マイクロタイタープレートへのペプチド結合及び最適な飽和ペプチド濃度を、アルカリホスファターゼ−ペプチド競合アッセイを用いて評価した。それぞれの血清の個々のバックグラウンド反応性をモニタリングするために、p16INK4aタンパク質(p16_76〜105)から誘導される対照ペプチドを使用したが、これに対する抗体反応性は大きな個体集団(cohort)においては見出されなかった(Reuschenbach et al., 2008)。それぞれの血清をブロッキング緩衝液(PBS中、0.5%カゼイン)で1:100に希釈し、全てのFSP及び対照ペプチドに対する抗体の存在に関して二連で試験した。プレート間の分散の参照として、プレートごとに1つの対照血清を含め、対照血清のペプチド特異的なODを正規化に使用した。希釈血清(50μl/ウェル)を1時間インキュベートし、洗浄工程後、プレートをHRP標識ウサギ抗ヒトIgG抗体(Jackson Immunoresearch, West Grove, PA;ブロッキング緩衝液中、1:10000)と1時間インキュベートした。洗浄後、50μl/ウェルのTMB基質(Sigma, Deisenhofen, Germany)を添加し、30分後に50μl/ウェルの1N H2SO4を添加することにより酵素反応を停止させた。吸光度を450nmで測定した(参照波長595nm)。特異性の制御のための血清抗体の前吸収は、Reuschenbach et al., 2008において詳細に記載された方法に従って行った。
FSP特異的な抗体がMSI−H CRC患者、健常なリンチ症候群突然変異保因者、及び健常な対照の末梢血中で検出可能であるかどうかを調べるために、ELISA分析を実施した。AIM2(−1)、HT001(−1)、TAF1B(−1)及びTGFBR2(−1)から誘導される新たに設計されたFSPに対して顕著な反応性が観察された。ELISAの結果を図3に示している。
FSP特異的な細胞傷害性T細胞応答の検出
臨床FSP抗原による刺激時のエフェクターT細胞上でのCD107aの表面発現を測定した。CD107aアッセイを用いて、エフェクター細胞からのパーフォリン/グランザイムBを含有する細胞傷害性粒子の分泌を実証する。CD107a分子は細胞傷害性粒子の表面上で発現し、細胞傷害性T細胞応答との関連で粒子が放出される場合に、細胞表面上で検出可能となる。
Cunningham and Wells, Science 244 (1989), 1081-1085.
Fingl et al., The Pharmocological Basis of Therapeutics, Goodman and Gilman, eds. Macmillan Publishing Co., New York, pp. 1-46 (1975).
Kloor M, Michel S, von Knebel Doeberitz M.
Immune evasion of microsatellite unstable colorectal cancers.
Int J Cancer. 2010 Mar 2. [Epub ahead of print]
Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer. 2001 Jul 1;93(1):6-11.
Reuschenbach M, Waterboer T, Wallin KL, Einenkel J, Dillner J, Hamsikova E, Eschenbach D, Zimmer H, Heilig B, Kopitz J, Pawlita M, von Knebel Doeberitz M, Wentzensen N.
Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers.
Int J Cancer. 2008 Dec 1;123(11):2626-31.
Reuschenbach M, Kloor M, Morak M, Wentzensen N, Germann A, Garbe Y, Tariverdian M, Findeisen P, Neumaier M, Holinski-Feder E, von Knebel Doeberitz M.
Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
Fam Cancer. 2009 Dec 2. [Epub ahead of print]
Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M. Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol. 2003 Sep;23(5):415-23.
Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology. 2008 Apr;134(4):988-97.
Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun. 2004 Nov 25;4:14.
配列表
Claims (11)
- MSI特異的なフレームシフトペプチド(FSP)の組合せ、並びにアジュバント、及び/又は免疫賦活性のサイトカイン若しくはケモカインを含有する、結腸直腸がんを予防又は治療する方法において使用されるワクチンであって、該FSPが以下のアミノ酸配列からなる、ワクチン。
NTQIKALNRGLKKKTILKKAGIGMCVKVSSIFFINKQKP(TAF1B(−1))、
EIFLPKGRSNSKKKGRRNRIPAVLRTEGEPLHTPSVGMRETTGLGC(HT001(−1))、及び
HSTIKVIKAKKKHREVKRTNSSQLV(AIM2(−1)) - 前記FSPがTag配列を更に含有する、請求項1に記載のワクチン。
- 請求項1又は2に記載のFSPをコードする核酸配列又は該核酸配列を含有するベクターを含有する、結腸直腸がんを予防又は治療する方法において使用されるワクチン。
- 前記ベクターがプラスミド又はウイルスベクターである、請求項3に記載のワクチン。
- 前記ウイルスベクターがポックスウイルス、アデノウイルス、レトロウイルス、ヘルペスウイルス、アルファウイルスベースのベクター又はアデノ随伴ウイルス(AAV)ベクターである、請求項4に記載のワクチン。
- 前記ポックスウイルスがワクシニアウイルス、NYVAC、アビポックスウイルス、カナリア痘ウイルス、ALVAC、ALVAC(2)、鶏痘ウイルス又はTROVACである、請求項5に記載のワクチン。
- 前記FSP、前記核酸配列又は前記ベクターが水中油型又は油中水型のエマルションビヒクル中に存在する、請求項1〜6のいずれか一項に記載のワクチン。
- 1つ又は複数の他の抗原を更に含む、請求項1〜7のいずれか一項に記載のワクチン。
- 結腸直腸がんの予防又は治療用のワクチンの調製のための請求項1又は2に記載のMSI腫瘍特異的なフレームシフトペプチド(FSP)、請求項3に記載の核酸、又は請求項3〜6のいずれか一項に記載のベクターの使用。
- 高リスク群の予防ワクチン接種のための請求項9に記載の使用。
- 前記結腸直腸がんが遺伝性非ポリープ性結腸直腸がん(HNPCC)である、請求項1に記載のワクチン。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012272828A JP5890769B2 (ja) | 2012-12-13 | 2012-12-13 | がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012272828A JP5890769B2 (ja) | 2012-12-13 | 2012-12-13 | がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015149569A Division JP2016028025A (ja) | 2015-07-29 | 2015-07-29 | がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp) |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014118361A JP2014118361A (ja) | 2014-06-30 |
JP2014118361A5 JP2014118361A5 (ja) | 2015-10-15 |
JP5890769B2 true JP5890769B2 (ja) | 2016-03-22 |
Family
ID=51173521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012272828A Active JP5890769B2 (ja) | 2012-12-13 | 2012-12-13 | がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp) |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5890769B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110996990A (zh) * | 2017-06-02 | 2020-04-10 | 亚利桑那州立大学董事会 | 通用癌症疫苗及其制备和使用方法 |
EP3652606B1 (en) * | 2017-07-12 | 2023-01-11 | Nouscom AG | A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
WO2003087162A2 (en) * | 2002-04-18 | 2003-10-23 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
-
2012
- 2012-12-13 JP JP2012272828A patent/JP5890769B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014118361A (ja) | 2014-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10682402B2 (en) | MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer | |
KR102351555B1 (ko) | Hpv 및 관련 질환용 면역 증강 치료 백신 | |
RU2329824C2 (ru) | Активная иммунотерапия против ангиогенеза | |
JP4540033B2 (ja) | 腫瘍抗原に対する免疫応答を誘発および/または増強する方法 | |
KR101810840B1 (ko) | 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp) | |
EP2572725B1 (en) | MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer | |
CN112867502A (zh) | Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗 | |
JP5890769B2 (ja) | がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp) | |
JP2016028025A (ja) | がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp) | |
AU2016201986B2 (en) | MSI-specific Frameshift Peptides (FSP) for Prevention and Treatment of Cancer | |
CA2799803C (en) | Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer | |
RU2805196C2 (ru) | Неоантигены и их применение | |
US20150313979A1 (en) | P16ink4a derived peptides for prophylaxis and therapy of hpv-associated tumors and other p16ink4a expressing tumors | |
JP5946759B2 (ja) | HPV関連腫瘍及び他のp16INK4a発現腫瘍の予防法及び治療法のためのp16INK4a由来ペプチド | |
EP1373505A2 (en) | Tri-hybrid melanoma antigen | |
JP2009541235A (ja) | 核酸ワクチンのアジュバンド作用のためのppdの使用 | |
AU2002244196A1 (en) | Tri-hybrid melanoma antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140801 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140806 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141003 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141105 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150729 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150729 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20151005 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160216 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5890769 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |